Dr. Bo Hedlund joins NDA Partners

December 20, 2017

 

 

Bo Hedlund, PhD, joined NDA Partners as an Expert Consultant.  He is currently an Adjunct Professor of Medicine at the University of Minnesota Medical School.
 

During his academic career at the University, Dr. Hedlund conducted research on hemoglobin chemistry and the role of iron in biology and medicine. He subsequently left the University to become President and CEO of Biomedical Frontiers, Inc., a start-up drug development company he co-founded. In this capacity he was responsible for initial patent applications and supervised pre-clinical and clinical submissions for a novel iron binding drug. This drug technology may have several applications in areas of hematology.
 

Dr. Hedlund is a Distinguished Emeritus Member of the American Society of Hematology. He has served, over the last decade, as an external reviewer of SBIR applications submitted to the National Heart, Lung and, Blood Institute (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 

 

Dr. Hedlund's Practice Area Focus
Drugs, Biologics, Diagnostics, Generics, CMC, Preclinical Study Design, Development Strategy, Clinical Pharmacology, Drug Safety and Toxicology

 

 

NDA Partners was founded in 2003 by a group of ten former senior regulatory agency staff, pharmaceutical industry executives, and academic experts who have played a major role in medical product development, drug regulations and program management over the past several decades. The company has focused on improving the development efficiency and speed and commercial success rate of medical products since its founding. A formal methodology was developed (Principles of Optimal Product Development) to provide high-level guidance for conducting strategic and assessment-orientated engagements. Originally, our customers were emerging biopharmaceutical companies and life sciences investment funds, and our services now include international pharma companies entering the US market, law firms involved in medical product litigation, research and development-oriented government agencies, and health care organizations.

More...

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Nanomedicine Short Course @ UMN MN Nano Center

May 18, 2018

1/7
Please reload

Recent Posts